Despite various methods currently used in cancer therapy, breast cancer remains the leading cause of morbidity and mortality worldwide. Current therapeutics face limitations such as multidrug resistance, drug toxicity and off-target effects, poor drug bioavailability and biocompatibility, and inefficient drug delivery. Nanotechnology has emerged as a promising approach to cancer diagnosis, imaging, and therapy. Several preclinical studies have demonstrated that compounds and nanoparticles formulated from platinum group metals (PGMs) effectively treat breast cancer. PGMs are chemically stable, easy to functionalise, versatile, and tunable. They can target hypoxic microenvironments, catalyse the production of reactive oxygen species, and offer the potential for combination therapy. PGM nanoparticles can be incorporated with anticancer drugs to improve efficacy and can be attached to targeting moieties to enhance tumour-targeting efficiency. This review focuses on the therapeutic outcomes of platinum group metal nanoparticles (PGMNs) against various breast cancer cells and briefly discusses clinical trials of these nanoparticles in breast cancer treatment. It further illustrates the potential applications of PGMNs in breast cancer and presents opportunities for future PGM-based nanomaterial applications in combatting breast cancer.

Folate receptor-targeted therapy has excellent prospects for the treatment of breast cancer. A non-toxic concentration of folate-conjugated palladium-based nanoparticles was used to target the overexpressed folate receptor on breast cancer cells. The folate-conjugated nanoparticles were tailored to accumulate selectively in cancer cells relative to normal cells via the folate receptor. The MDA-MB-231, MDA-MB-468, MCF-7 breast cancer cell lines, and MCF-10A normal cell lines were used in the study. Qualitative and quantitative analysis of nanoparticle cellular uptake and accumulation was conducted using transmission electron microscopy and inductively coupled plasma-optical emission spectroscopy. The findings proved that folate-conjugated palladium nanoparticles successfully and preferentially accumulated in breast cancer cells. We conclude that folate-conjugated palladium nanoparticles can be potentially used to target breast cancer cells for radiopharmaceutical applications.

A novel alternative route to access rhenium(V)−phthalocyanine complexes through direct metalation of metal‐free phthalocyanines (H₂Pcs) with a rhenium(VII) salt in the presence of various two‐electron reducing agents is presented. Direct ion metalation of tetraamino‐ or tetranitrophthalocyanine with perrhenate (ReO₄⁻) in the presence of triphenylphosphine led to oxidative decomposition of the H₂Pcs, giving their respective phthalonitriles. Conversely, treatment of H₂Pcs with ReO₄⁻ employing sodium metabisulfite yielded the desired Re^VO−Pc complex. Finally, reaction of H₂Pcs with ReO₄⁻ and NaBH₄ as reducing agent led to the formation of rhenium oxide (Re_xO_y) nanoparticles (NPs). The NP synthesis was optimised, and the Re_xO_y NPs were capped with folic acid (FA) conjugated with tetraaminophthalocyanine (TAPc) to enhance their cancer cell targeting ability. The cytotoxicity profile of the resultant Re_xO_y−TAPc−FA NPs was assessed and found to be greater than 80 % viability in four cell lines, namely, MDA−MB‐231, HCC7, HCC1806 and HEK293T. Non‐cytotoxic concentrations were determined and employed in cancer cell localization studies. The particle size effect on localization of NPs was also investigated using confocal fluorescence and transmission electron microscopy. The smaller NPs (≈10 nm) were found to exhibit stronger fluorescence properties than the ≈50 nm NPs and exhibited better cell localization ability than the ≈50 nm NPs.

Conventional chemical and physical methods for nanoparticle synthesis often involve toxic reagents, high energy demands, and limited biocompatibility. As a result, the biosynthesis of precious metal nanoparticles (PMNPs) using green algal extracts has gained attention as an eco-friendly, low-cost alternative, particularly for biomedical applications. This review explores the synthesis of PMNPs, i.e., silver, gold, platinum, palladium, rhodium, iridium, osmium, and ruthenium, via green algae, emphasizing the role of algal metabolites and phytochemicals in nanoparticle reduction and stabilization. Biosynthesized PMNPs consistently exhibit strong anticancer properties, including dose-dependent cytotoxicity, reactive oxygen species generation, apoptosis induction, and selective activity against cancer cells, especially in breast, cervical, liver, and colorectal cancer models. However, challenges such as limited mechanistic understanding, variability in synthesis outcomes, and scalability constraints remain. This review highlights the cancer therapeutic promise of green algae-mediated PMNPs while outlining critical directions for future research in anticancer nanomedicine.